Cv peter short

PETER DAVID EISENBERG, M.D., FACP

PROFESSIONAL

Address:
1350 South Eliseo Drive, Suite 200 Greenbrae, California 94904-2007
EDUCATION
1963-67
M.D., Hahnemann Medical College, Philadelphia, Pennsylvania Internship: Internal Medicine Jacksonville Hospitals Education Program University of Florida Residency: Internal Medicine, Graduate Medical Education Jacksonville Hospitals Education Program Fellowship: Hematology & Oncology, Assistant Research Physician
PROFESSIONAL ACTIVITIES

2011 - present
Practitioner of Hematology and Medical Oncology Peter David Eisenberg, M.D., FACP
Practitioner of Hematology and Medical Oncology Member, American Society of Clinical Oncology Medical Director, Marin Cancer Institute Association of Northern California Oncologists QUALITY ACTIVTIES
Member, ASCO Quality Oncology Practice Initiative Member, NCI Working Group: Using Management Science and Engineering
to Improve Cancer Care Delivery. Tuesday, August 31, 2010
Member, ASCO Quality Oncology Practice Initiative Member, RAND Health Expert Panel on supportive cancer measures Member, National Quality Forum Cancer Care Quality Member, Institute of Medicine Committee to Assess Member, NCI Committee to plan "An Idealized Design for Cancer Care” Member, Expert Panel “Transforming Health Systems through Leadership, Design, and Incentives” sponsored by the Agency for Healthcare Research and Quality (AHRQ), CMS and NCI Member, ASCO Quality Oncology Practice Initiative
1995-2000
Member, Health Services Research Committee, ASCO C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc Peter David Eisenberg, M.D., FACP

RESEARCH ACTIVITIES

2000 - present
Chairman, Marin General Hospital Institutional Review Board Principal Investigator, Marin Specialty Care Research Program
1977 – present
Ongoing Clinical Phase I, II, III, and IV Pharmaceutical Oncology Trial experience as the Principal Investigator; to date, involved in over 500 Principal Investigator, Sutter Health, Cancer Research Group Associate Scientist, Geraldine Brush Cancer Research Institute, Medical Principal Investigator, National Surgical Adjuvant Breast and Bowel Project Member, Executive Committee, National Surgical Adjuvant Breast and Principal Investigator, California Healthcare Systems Community Clinical
1984 - 1989
Principal Investigator, Northern California Oncology Group CERTIFICATIONS AND LICENSES
Diplomate, American Board of Internal Medicine, Medical Oncology Diplomate, American Board of Internal Medicine, Internal Medicine Diplomate, National Board of Medical Examiners, #125175
MEMBERSHIPS AND POSITIONS
Member, Information Technology Committee, ASCO C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc Peter David Eisenberg, M.D., FACP
Member, Physicians Relations Committee, Blue Cross of California Member, Board of Directors, Hospice of Marin San Francisco Regional Cancer Foundation Host, KCBS Radio, Health Magazine
President Student Body, Hahnemann Medical College Member, Senior Honor Society, Franklin and Marshall College
PUBLICATIONS
Eisenberg, P.D., Aster, R.H., and Abramson, N.:"Post-Transfusion Purpura: New Aspects of
Diagnosis and Therapy." (Abstract) American Society of Hematology. Blood, (1974).
Abramson, N., Eisenberg, P.D., and Aster, R.H.: "Post-Transfusion Purpura: Immunologic Aspects
and Therapy." New England Journal of Medicine. 291:1163-1166 (November 28, 1974).
Eisenberg, P.D. and Abramson, N.: "Post -Transfusion Purpura Revisited." (letter) New England
Journal of Medicine. 296:515-516 (March 3, 1977).
Mohandas, N., Clark, M.R., Wyatt, J.F., Eisenberg, P.D., and Shohet, S.B.: "Erythropoietic Stress,
Macrocytosis and Hemoglobin Switching in HbAA Sheep." Blood. 55:757-761 (May, 1980).
C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc Peter David Eisenberg, M.D., FACP
Wickerham, L., Fisher, B., Cronin, W., Stollbach, L., Abramson, N., Bowman, D., Deckers, P.J., Eisenberg, P.D., Foster, R., Glass, A., Kay, S., Kyle, A., Prager, D. and Pritchard, K.: "The Efficacy
of Bone Scanning in the Follow-Up of Patients with Operable Breast Cancer." Breast Cancer
Research and Treatment. 4:303-307 (1984).
Valone, F.H., Friedman, M.A., Wittlinger, P.F., Drakes, T., Eisenberg, P.D., Brown, B.W., Malec,
M., Hannigan, J.: "Treatment of Patients with Advanced Colorectal Carcinomas with 5-FU Alone,
High Dose Leucovorin Plus 5-FU or Sequential Methotrexate, 5-FU, Leucovorin: A Randomized
Trial of the Northern California Oncology Group." J Clin Oncol.7:1427-1436 (October, 1989)
Carlson, R.W., Borrison, R.A., Sher, H.B., Eisenberg, P.D., Mowry, P.A., Wolin, E.M.: "A
multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine,
acetaminophen plus codeine, and placebo in cancer pain." Pharmacotherapy 1990;10(3):211-6.
Valone, F.H., Wittlinger, P.S., Flam M.S., Drakes, T., Eisenberg, P.D., Hannigan, J.: "A northern
California Oncology Group randomized trial of single agent 5-FU vs. high-dose folinic acid + 5-FU
vs. methotrexate + 5-FU + folinic acid in patients with disseminated measurable large bowel cancer."
Adv Exp Med Biol 1988:244:193-9.
Plezia, P., Modiano, M., Alberts, D., Bertoli, L., Yielding A., Eisenberg, P., Khojasteh A., Gandara
D., Heck, K., Hahne, W.: "A double-blind, randomized, parallel study of two doses of intravenous
(IV) MDL 73, 147EF in patients (pts) receiving high dose Cisplatin (CDDP)-Containing
Chemotherapy (CT)." Proceedings of ASCO March 1992:V. Vol. 11: p407.
LeVeque, Francis G, Parzuchowski, Jeanne B., Farinacci, George C., Redding, Spencer W., Rodu,
Brad, Johnson, Jonas T., Ferretti, Gerald A., Eisenberg, Peter D., and Michael B. Zimmer.:
"Clinical Evaluation of MGI 209, an anesthetic film-forming agent for relief from painful oral ulcers
associated with chemotherapy." Journal of Clinical Oncology, Vol 10, No. 12 (December),
1992:pp1963-1968.
Poplin, Elizabeth, Fleming, Tom, MacDonald, John S., Eisenberg, Peter, Fisher, Richard I., and
Conrad, Marcel E.: "Amonafide Treatment of Refractory Esophageal Cancer" Investigational New
Drugs, Vol 11:pp47-51, 1993.
Burris, H., Vogel, C., Schwarz, M., Spencer, S., Lentz, M., Abramson, N., Eisenberg, P., Fleming,
G, George, S., Sher, H., Lopez, L., Baughman, J., and Korey A. "A Phase I/II Multi-center Clinical
Trial of the Cisplatin Therapeutic Implant (MPI 5010) for Treatment of Solid Tumors." (Abstract
#1369) ASCO Proceedings, Vol 13:pp402 1994.
Grunberg, S., Andrews, P., Dilly, S., Perez, A. & Gandara, D., Palmer, R., Eisenberg, P. “Further
profiles of Granisetron (Kytril): Effect on Quality of Life and Pharmacoeconomics” Seminars in
Oncology, June 1994: pp26-28.
E. Rubenstein, L. Kalman, J. Hainsworth, P. Plezia, M. Modiano, P. Eisenberg, P. Hesketh, K.
Frieze, J. Whitmore, M. Cramer, W. Hahne. “Dose Response Trial Across 4 Oral Doses of
Dolasetron (D) for Emesis Prevention After Moderately Emetogenic Chemotherapy (CT).” (Abstract
#1737) ASCO Proceedings, Vol 14:pp527 1995.
Buzdar, A.U., Plourde, S.E., Jones, S.E., Vogel, C.L., Wolters,J.M., Eisenberg, P.D. and the N
American Arimidex Study Group:"Randomized phase III study of the new selective aromatase
inhibitor arimidex (A) (ZD1033) versus megestrol acetate (MA) in the treatment of postmenopausal
women with advanced breast cancer." (Abstract #104) 4th Nottingham International Breast Cancer
Conference Breast, Vol 4 (3):pp256-257 1995.
C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc Peter David Eisenberg, M.D., FACP

Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E,
Bellet RE. “Phase II Trial of Docetaxel in Advanced Anthracycline-resistant or Anthracenedione-
resistant Breast Cancer.” Journal of Clinical Oncology, Vol. 13 No. 12 (December), 1995: pp2879-
2885.
Ettinger DS, Eisenberg P, Fitts D, Friedman C, Wilson-Lynch K, Yocom K. “A Double-Blind
Comparison of the Efficacy of Two Dose Regimens of Oral Granisetron in Preventing Acute Emesis
in Patients Receiving Moderately Emetogenic Chemotherapy.”
Cancer, Vol. 78, No. 1 (July) 1996: pp 144-151.
Gradishar WJ, Loh K, Erban J, Vogel C, Grabelsky S, Cohen R, Limentani S, Woodard W, Dobbs T,
Eisenberg P, Swain S. “Preliminary results from a phase II study of (Taxotere  [T]) docetaxel as
primary chemotherapy (PCT) followed by doxorubicin (A) and cyclophosphamide (C) in stage III
breast cancer.” Proceedings of ASCO, Vol. 16, 1997: p 171a.
Jones S, Vogel C, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Arkhipov A, Tiffany J, Polli A,
Whaley F, diSalle E, Consonni A, Miller L. Antitumor efficacy of exemestane as third-line hormonal
therapy in the treatment of postmenopausal women with metastatic breast cancer refractory to
Tamoxifen and MegaceTM , Proc ASCO 1998, 17, p. 150a, abstr 573.
Jones S, Vogel C, Fehrenbacher L, Eisenberg P, Tiffany J, Polli A, Whaley F, diSalle E, Consonni
A, Miller L. A phase II study of antitumor efficacy of exemestane as third-line hormonal treatment of
postmenopausal women with metastatic breast cancer refractory to Tamoxifen and MegaceTM . Proc
23rd Congress of the ESMO, 1998. Ann Oncol 1998, 9 (Suppl 4), p.13, abstr, 64P.
Lonning PE, Bajetta E, Murray R, Tubiana M, Eisenberg P, Mickiewicz E, Fowst C, Arkhipov A,
Polli A, diSalle E, Massimini G. A phase II study of exemestane in metastatic breast cancer patients
failing non steroidal aromatase inhibitors. Proc 21st Annual San Antonio Breast Cancer Symposium,
1998. Beast Cancer Res Treat, 1998, 50, p. 304, abstr. 435.
Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F,
di Salle E, Tiffany J, Consonni A, and Miller L. “Multicenter, Phase II Trial of Exemestane as Third-
Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer.” Journal of
Clinical Oncology, Vol. 17, No. 11 (November), 1999: pp 3418-3425.
Moore M, Hamm J, Eisenberg P, Dagenais M, Hagan Kate Ackenheil, Fields A, Greenberg B,
Schwartz B, Ottaway J, Zee B, Seymour L. “A Comparison Between Gemcitabine (GEM) and the
Matrix Metalloproteinase (MMP) Inhibitor BAY 12-9566 (9566) in Patients (Pts) with Advanced
Pancreatic Cancer.” Proceedings of ASCO, Vol. 19, May 20-23, 2000: p 240a.
Rizvi N, Eisenberg P, Reich S. “Placebo-Controlled Trial of Bexarotene (Targretin, LGD1069), a
Retinoid X Receptor (RXR) Agonist, as Maintenance Therapy for Patients Treated with
Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC): AL1069-20 Study Group
Trial.” Proceedings of ASCO, Vol. 19, May 20-23, 2000: p 535a.
Lonning P, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg P, Mickiewicz E, Celio L, Pitt P, Mita
M, Aaronson N, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G. “Activity of Exemestane in
Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial.”
Journal of Clinical Oncology, Vol. 18, No. 11 (June), 2000: pp 2234-2244.
Schapira L, Eisenberg P, MacDonald N, Mumber M, and Loprinzi C. “The Art of Oncology: When
the Tumor is Not the Target. A Revisitation of ‘Doc, How Much Time Do I Have?’ ” Journal of
Clinical Oncology, Vol. 18, No. 13 (July), 2000: pp 2640-2643.
C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc Peter David Eisenberg, M.D., FACP

Rizvi N, Hawkins M, Eisenberg P, Yocum R, Reich S and the Ligand L1069-20 Working Group.
“Placebo-Controlled Trial of Bexarotene, a Retinoid X Receptor Agonist, as Maintenance Therapy
for Patients Treated with Chemotherapy for Advanced Non-Small Cell Lung Cancer.” Clinical Lung
Cancer, Vol. 2, No. 3, February 2001: pp 210-215.
Buzdar A, Hayes D, El-KhoudaryA, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard
K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, and Eisenberg P. “Phase III
randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive
advanced breast cancer.” Breast Cancer Research and Treatment, Vol 73, 2002: pp161–175.
N.A. Rizvi, W. Miller, Hfrank, D. Small, J. Aisner, P. Eisenberg, G.R. Blumenschein, F. Khuri.
“Phase I/II safety evaluation of bexarotene in combination with carboplatin and paclitaxel in patients
with chemotherapy-naïve advanced non-small cell lung cancer. (NSCLC.”) Proceedings of ASCO,
Vol. 19, May 18-21, 2002: p 1334.
Douillard J-Y, Hoff P, Skillings J, Eisenberg P, Davidson N, Harper P, Vincent M, Lembersky B,
Thompson S, Maniero A, and Benner S. “Multicenter Phase III Study of Uracil/Tegafur and Oral
Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic
Colorectal Cancer.” Journal of Clinical Oncology, Vol 20, No 17 (September 1), 2002: pp 3605-3616.
Lichtman S, Etcubanas E, Budman D, Eisenberg P, Zervos G, D’Amico P, O’Mara V, Musgrave K,
Cascella P, Melikian A, Hinderling P, Ferrer J, and Williams G. “The Pharmacokinetics and
Pharmacodynamics of Fludarabine Phosphate in Patients with Renal Impairment: A Prospective Dose
Adjustment Study.” Cancer Investigation, vol. 20, No 7 & 8, 2002: pp 904-913.
Cohen L, De Moor C, Eisenberg P, Grunberg SM, Kim YJ, and Rubenstein EB. “Delayed
chemotherapy-induced nausea and vomiting (CINV) remains a problem and significantly interferes
with daily function (DF) in pts receiving emetogenic chemotherapy (CT) in the United States.”
Proceedings of ASCO, Vol. 22, May 18-June 3, 2003: p 739.
Eisenberg PD, Rubenstein EB, Cohen L, De Moor C, Kim YJ, and Grunberg SM. “Perceptions and
satisfaction (S) of oncologists (MDs) and oncology nurses (RNs) of antiemetic therapy (AET) for
chemotherapy-induced nausea and vomiting (CINV) vs. patient experiences after emetogenic
chemotherapy (CT) in the US.” Proceedings of ASCO, Vol. 22, May 18-June 3, 2003: p 740.
Demoor C, Cohen L, Eisenberg PD, Grunberg SM, Kim YJ, and Rubenstein EB. “Oncologists'
compliance with antiemetic guidelines (AEG) and outcomes of patients (pts) receiving emetogenic
chemotherapy (CT).” Proceedings of ASCO, Vol. 22, May 18-June 3, 2003: p 727.
Rubenstein EB, Gralla RJ, Eisenberg P, Sleeboom, Vtoraya O, Macciocchi A, Olivares G, and Berry
D. “Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for Prevention of
Acute & Delayed Chemotherapy-Induced Nausea and Vomiting (CINV): Combined Results of Two
Phase III Trials.” Proceedings of ASCO, Vol. 22, May 18-June 3, 2003: p 727.
Cohen L, de Moor C, Eisenberg PD, Kim YJ, Ming, E, Kanesan K, and Rubenstein EB.
“Expectations of Side Effects are Associated with Health Status and Fatigue in Patients receiving
Chemotherapy (CT).” Proceedings of MASCC, Vol. 11, June 18-21, 2003: p 403.
C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc Peter David Eisenberg, M.D., FACP

de Moor C, Cohen L, Eisenberg PD, Kim YJ, Ming, E, and Rubenstein EB. “Patterns if
Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (PTS) Receiving Chemotherapy.”
Proceedings of MASCC, Vol. 11, June 18-21, 2003: p 395.
Moore MJ, Hamm, J. Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B,
Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, and L. Seymour. “Comparison of Gemcitabine
versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic
Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada
Clinical Trials Group.” Journal of Clinical Oncology, vol. 21, No 17, (September 1), 2003: pp 3296-
3302.
Rosen LS, Gordon DH, Dugan Jr. W, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone
J, Seaman J, Chen B-L, Coleman RE. “Zoledronic acid is superior to pamidronate for the treatment of
bone metastases in breast carcinoma patients with at least one osteolytic lesion.” Cancer, vol. 100,
No. 1, (January1), 2004: pp36-43.
Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM,
Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, and
Renschler MF. “Neurocognitive Function and Progression in Patients With Brain Metastases Treated
With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial.”
Journal of Clinical Oncology, vol. 22, No 1, (January 1), 2004: pp 157-165.

Eisenberg PD, MacKintosh FR, Ritch P, Cornett PA, and Macciocchi A. “Efficacy, safety and
pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based
chemotherapy: a dose-ranging clinical study.” Ann Oncol 15, February 2, 2004: pp330-337.
Warr DG, Eisenberg P, Hesketh PJ, Gralla RJ, Raftopolous H, Gabriel M, Rodgers A, Klinger G,
Hustad CM, Skobieranda F. “Effect of aprepitant for the prevention of nausea and vomiting after one
cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients.”
Proceedings of MASCC, Vol. 12, Number 6, (June 2004): p 374
Rubenstein EB, De Moor C, Cohen L, Klahn C, Eisenberg P “Outcomes of patients (pts) receiving
emetogenic chemotherapy (CT): How do oncologist’s (MD’s) practice patterns of antiemetic
prescribing change after pts experience acute or delayed CINV?” Proceedings of ASCO, Vol 23,
June 5-8, 2004: p 788, Abstract No: 8256
Cohen RB, Simon G, Langer CJ, Schol JR, McHale J, Eisenberg P, Hainsworth JD, Liau KF,
Healey D. “Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and
carboplatin (C) in advanced non-small cell lung cancer (NSCLC).” Proceedings of ASCO, Vol. 23,
June 5-8, 2004: p 198. Abstract No: 3014
Desch CE, Eisenberg P, Gesme D, Jacobson J, Jahanzeb M, Neuss M, Padberg J, Rainey J, Simone
J. “A practice-based, voluntary program for promoting excellence in cancer care: A pilot study of
feasibility, cost and preliminary results.” Proceedings of ASCO, Vol. 23, June 5-8, 2004: p. 524.
Abstract No: 6029
C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc Peter David Eisenberg, M.D., FACP

Jacobs AD, Burris HA, Rivkin S, Ritch PS, Eisenberg PD, Mettinger KL. “A randomized phase III
study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report
from a North-American multi-center study.” Proceedings of ASCO, Vol. 23, June 5-8, 2004: p 315.
Abstract No: 4013
Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg
SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. “Efficacy
and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in
Patients With Breast Cancer After Moderately Emetogenic Chemotherapy.” Journal of Clinical
Oncology, vol. 23, No 12, (April 20), 2005: pp 2822-2830.
Eden J, Simone JV, Eds. (Eisenberg PD, Committee Member). “Assessing the Quality of Cancer
Care: An Approach to Measurement in Georgia. A report of the National Cancer Policy Board of the
Institute of Medicine. Washington, DC, National Academy Press, 2005.

Neuss MN, Desch CE, McNiff KK, Eisenberg PD, Gesme DH, Jacobson JO, Jahanzeb M, Padberg
JJ, Rainey JM, Guo JJ, and Simone JV. “A Process for Measuring the Quality of Cancer Care: The
Quality Oncology Practice Initiative.” Journal of Clinical Oncology, vol. 23, No 25 (September 1)
2005:pp 6233-6239.
Cohen RB, Langer CJ, Simon RJ, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM,
Pierce K, Xu Hu, Liau K and Healey D. “A phase I/randomized phase II, non-comparative, multi-
center, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel
and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).”
electroniWednesday, October 11, 2006
Cohen L, de Moor CA, Eisenberg P, Ming EE and Hu H. “Chemotherapy-induced nausea and
vomiting—incidence and impact on patient quality of life at community oncology settings.”
Supportive Care in Oncology,” electroniWednesday, November 15, 2006
J.O. Jacobson, M.N. Neuss, K. McNiff, P. Kadlubek, L.R.Thacker II, P.D. Eisenberg, J.V. Simone;
“Improvement in oncology practice performance through voluntary participation in the Quality
Oncology Practice Initiative (QOPI) Proceedings of ASCO, Vol. 25, June 20, 2007: p 323. Abstract
No: 6505 Oral Presentation
D.D.Karp, L.G. Paz-Ares, L.J. Blakely, H. Kreisman, P.D. Eisenberg, R.B. Cohen, L. Garland, C.J.
Langer, C.L. Melvin, A. Gualberto; “Efficacy of the anti-insulin like growth factor I receptor (IGF-
IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for
advanced non-small cell lung cancer (NSCLC).” Proceedings of ASCO, Volume 25, June 20, 2007: p
386. Abstract No: 7506
R.W. Ross, M. Stein, J. Sarantopoulos, P.Eisenberg, T. Logan, S. Srinivas, J. Rosenberg, U.
Vaishampayan; “A phase II study of the c-Met RTX inhibitor XL880 in patients (pts) with papillary
renal-call carcinoma (PRC).” Proceedings of ASCO, Volume 25, June 20, 2007: p 658. Abstract No:
15601
C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc Peter David Eisenberg, M.D., FACP

L. Cripe, W. McGuire, M.Wertheim, P. Eisenberg, W. Stadler, R.Paquette, T.Logan, T. Zimmerman,
D. Matei, U. Matulonis, “Integrated report of the phase 2 experience with XL999 administered IV to
patients (pts) with NSCLC, renal cell CA(RCC), metastatic colorectal CA(CRC), recurrent ovarian
CA, acute myelogenous leukemia (AML) and multiple myeloma (MM).” Proceedings of ASCO,
Volume 25, June 20, 2007: p.160 Abstract 3591
HJ Burstein, AD Elias, HS Rugo, MA Cobleigh, AC Wolff, PD Eisenberg, ML BJ Adams, CL Bello,
SE DePrimo, CM Baum, KD Miller, “Phase II Study of Sunitinib Malate, an Oral
MultitargetedTyrosine Kinase Inhibitor, in Patients With MetastaticBreast Cancer Previously Treated
With an Anthracycline and a Taxane.” Journal of Clinical Oncology, vol. 26, No 11 (April 10) 2008:
pp 1810-1816.
JO Jacobson, MN Neuss, KK McNiff, P Kadlubek, LR Thacker, F Song, PD Eisenberg, and JV.
Simone, “Improvement in Oncology Practice Performance through Voluntary Participation in the
Quality Oncology Practice Initiative (QOPI).” Journal of Clinical Oncology, vol. 26, No 11 (April
10) 2008: pp 1893-1898.
KK McNiff, MN Neuss, JO Jacobson, PD Eisenberg, P Kadlubek, and JV Simone, “Measuring
Supportive Care in Medical Oncology Practice: Lessons Learned From the Quality Oncology Practice
Initiative.” Journal of Clinical Oncology, vol26, No 23 (August 10) 2008: pp 3832-3837.
DD Karp, LG Paz-Ares, S Novello, P Haluska, L Garland, F Cardenal, LJ Blakely, PD Eisenberg, CJ
Langer, G Blumenschein Jr, FM Johnson, S Green, and A Gualberto, “Phase II Study of the Anti–
Insulin-Like Growth Factor Type1 Receptor Antibody CP-751,871 in Combination With Paclitaxel
and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung
Cancer.” Journal of Clinical Oncology, Apr 20 2009: doi:10.1200/JCO.2008.19.9331
MN Neuss, JO Jacobson, , KK McNiff, P Kadlubek, PD Eisenberg, and JV. Simone, “Evolution and
Elements of the Quality Oncology Practice Initiative Measure Set.” Cancer Control, vol. 16, No 4
October, 2009 pp312-317.
EB. Haura, AD Ricart, TG Larson, PJ Stella, L Bazhenova, VA Miller, RB Cohen, PD Eisenberg, P
Selaru, KD Wilner, and SM Gadgeel. “A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in
Previously Treated Patients with Advanced Non–Small Cell Lung Cancer.” Clin Cancer Res, April
15, 2010, vol 10 pp1158-1078.
LS KWC Hermann, G JJ
PR
DC N CSorafenib
With Gemcitabine or Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer That
Progressed During or After Bevacizumab.”2013 Feb 26. [Epub ahead of print]
BOOK CHAPTER

Achieving Career Success in Oncology; Job Application and Contract Negotiation in Community
Practice with Harvey D. Bichkoff; ASCO. Editor-in-Chief, Laura Hutchins, pp 219-235, 2008.
RECENT MAJOR PRESENTATIONS
C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc Peter David Eisenberg, M.D., FACP
& “Clinical Trials in the Community” Annual Meeting: Education Program Discussant, “Measuring Quality in an Office-Based Practice: the ASCO Quality Oncology Practice Initiative” Annual Meeting, “Quality Efforts in Oncology” Clinical Trials Workshop for the Community Oncology Team: “Engaging Annual Meeting: Special Session Discussant, “Issues in the Access if Annual Meeting: Education Session Discussant, “Evidence-Based Oncology Meets Clinical Experience: Challenges and Opportunities.” Annual Meeting: Educational Symposium Chair, “Using Quality to Survive C:\Users\tstorla\Desktop\CV Eisenberg 03-08-13.doc

Source: http://www.marinspecialtycare.com/files/2013/02/CV-Eisenberg-03-08-13.pdf